ARCH-backed SciNeu­ro kicks off search for CNS au­toan­ti­bod­ies with new deal; Mer­ck + Gilead an­nounce PhII tri­al for HIV com­bo

From the very be­gin­ning at SciNeu­ro, CEO Min Li has en­vi­sioned a mix of li­cens­ing deals and sci­en­tif­ic ef­forts to repli­cate the break­out suc­cess of Chi­na’s on­col­o­gy com­pa­nies in neu­ro­science.

The Glax­o­SmithK­line vet has now inked a deal that some­what strad­dles the line be­tween the two strate­gies.

Team­ing up with Maby­lon out of Zurich, SciNeu­ro is now look­ing to test the hy­poth­e­sis that the hu­man im­mune sys­tem can play a role in fight­ing neu­rode­gen­er­a­tive dis­eases by dis­cov­er­ing and de­vel­op­ing hu­man au­toan­ti­bod­ies against neu­ro­log­i­cal “tar­gets of mu­tu­al in­ter­ests.” The new part­ners of­fered TAR DNA bind­ing pro­tein-43 (TDP-43) and apolipopro­tein E (APOE), which are linked to ALS and Alzheimer’s, as ex­am­ples.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.